ArticleTobacco induced diseases2025
Comparative analysis of global and Chinese trends in the burden of ischemic stroke attributable to secondhand smoke from 1990-2021.
Article in Tobacco induced diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIschemic stroke (IS) represents a major health burden in China, and tobacco control is recognized as a practical and effective strategy to alleviate this impact. This study examines the influence of secondhand smoke (SHS) on the IS burden in China from 1990-2021.
methodsBased on data from the Global Burden of Disease (GBD) 2021, this study analyzed the mortality and disability-adjusted life years (DALYs) burden of ischemic stroke (IS) attributable to secondhand smoke (SHS) in China and globally from 1990 to 2021. This study examined trends across different age and sex groups and projected future mortality and DALYs, providing a scientific basis for targeted public health strategies.
resultsOver the past 32 years, the number of IS deaths from SHS exposure in China rose from 23394.83 (95% UI: 15837.47-32315.19) in 1990 to 53697.88 (95% UI: 35003.84-76382.65) in 2021. Despite this increase, the ASMR declined from 3.94 (95% UI: 2.59-5.54) per 100000 population in 1990 to 2.92 (95% UI: 1.88-4.21) in 2021, with an AAPC of -0.04 (95% CI: -0.04-0.03). However, China's ASMR and ASDR remain significantly higher than the global average. APC analysis revealed greater mortality trends among the elderly and females. Over the next 30 years, mortality rates will decline across all ages, but deaths will rise, especially in those aged 75 years and older.
conclusionsThe mortality rate of SHS-related IS in China declined from 1990 to 2021, but elderly and female patients still face a high burden. China's disease burden remains higher than the global average. While mortality rates may continue to decline, deaths are expected to rise, especially among those aged 75 years and older.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.